Q linea AB (QLINEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q linea AB (QLINEA) has a cash flow conversion efficiency ratio of -0.099x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-30.19 Million ≈ $-3.25 Million USD) by net assets (Skr304.55 Million ≈ $32.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see QLINEA stock market capitalisation for the company's overall valuation and market capitalisation.
Q linea AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Q linea AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Q linea AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q linea AB ranked by their cash flow conversion efficiency. See debt repayment capacity of Q linea AB to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Entain PLC
LSE:ENT
|
0.282x |
|
Yellow Balloon Tour Co. Ltd
KQ:104620
|
0.071x |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
0.079x |
|
GFM Services Bhd
KLSE:0039
|
0.040x |
|
Vince Holding Corp
NYSE:VNCE
|
0.085x |
|
Revoil S.A
AT:REVOIL
|
-0.040x |
|
Visi Media Asia Tbk
JK:VIVA
|
0.067x |
|
Rockhaven Resources Ltd
V:RK
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Q linea AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q linea AB from 2016 to 2025. View QLINEA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr338.00 Million ≈ $36.37 Million |
Skr-162.12 Million ≈ $-17.45 Million |
-0.480x | -107.22% |
| 2024-12-31 | Skr-27.46 Million ≈ $-2.95 Million |
Skr-182.50 Million ≈ $-19.64 Million |
6.647x | +651.58% |
| 2023-12-31 | Skr189.64 Million ≈ $20.41 Million |
Skr-228.52 Million ≈ $-24.59 Million |
-1.205x | +22.36% |
| 2022-12-31 | Skr161.63 Million ≈ $17.39 Million |
Skr-250.86 Million ≈ $-27.00 Million |
-1.552x | -162.15% |
| 2021-12-31 | Skr430.79 Million ≈ $46.36 Million |
Skr-255.05 Million ≈ $-27.45 Million |
-0.592x | +5.14% |
| 2020-12-31 | Skr380.20 Million ≈ $40.92 Million |
Skr-237.31 Million ≈ $-25.54 Million |
-0.624x | -25.36% |
| 2019-12-31 | Skr340.94 Million ≈ $36.69 Million |
Skr-169.76 Million ≈ $-18.27 Million |
-0.498x | -108.34% |
| 2018-12-31 | Skr513.46 Million ≈ $55.26 Million |
Skr-122.71 Million ≈ $-13.21 Million |
-0.239x | +99.43% |
| 2017-12-31 | Skr1.51 Million ≈ $162.72K |
Skr-62.87 Million ≈ $-6.77 Million |
-41.577x | -565.28% |
| 2016-12-31 | Skr8.45 Million ≈ $909.79K |
Skr-52.83 Million ≈ $-5.69 Million |
-6.250x | -- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more